1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Microbiome Therapeutics Market By Type (Fecal Microbial Transplant [FMT], Drugs) By Application (C. difficile, Crohn’s Disease, Inflammatory Bowel Disease [IBD], Diabetes), By Region And Segment Forecasts, 2014 - 2025

Microbiome Therapeutics Market By Type (Fecal Microbial Transplant [FMT], Drugs) By Application (C. difficile, Crohn’s Disease, Inflammatory Bowel Disease [IBD], Diabetes), By Region And Segment Forecasts, 2014 - 2025

  • December 2016
  • 80 pages
  • ID: 4604969
  • Format: PDF
  • By Grand View Research

Summary

Table of Contents

The microbiome therapeutics market is expected to reach USD 433.5 million by 2025, based on a new study by Grand View Research, Inc. Increasing funding initiatives and government programs to support this research are high impact rendering drivers anticipated to foster market growth.

The launch of Human Microbiome Project by NHS in Europe and the Microbiome Initiative by the U.S. government are some of the crucial government initiatives pertaining to market growth. The U.S. government has announced to have invested over USD 121 million in the Microbiome Initiative with additional USD 100 million from the Bill and Melinda Gates Foundation.

Presence of strong drug pipeline can also be attributed to the highly lucrative growth. Key players are entering into collaborative agreements with venture capital firms and research institutes for enhancing therapeutics pipeline through development of efficient and safe drugs. Some of the companies that recently formed collaborative agreements are Seventure Partners & ENTEROME Bioscience; Vedanta Biosciences & Johnson & Johnson Pvt. Ltd.; and Seventure Partners & Eligo Bioscience.


Further Key Findings from the Study Suggest:

Fecal Microbial Transplant (FMT) held the largest market share in 2015 owing to easier availability and introduction of FMT capsules by Open Biome

Introduction of RBX2660, a phase 3 molecule, during the end of 2018 will result in substantial increase in revenue of FMT

No commercial microbiome drugs are currently available with FMT being the only therapy for treatment. Drugs are estimated to hit the market by fourth quarter of 2017.

It is estimated that the drugs segment would witness the fastest growth owing to the presence of blockbuster drugs, such as, NM504, SER-109, RP-G28, and SGM-1019, in the pipeline

C. difficile dominated the application segment in 2015 with Crohn’s disease leading the market CAGR over the forecast period

North America held the largest share in 2015, owing to presence of major companies & established healthcare infrastructure and high amount of research activities

Asia Pacific is anticipated to witness significant growth with increasing acceptance of FMT in developing countries, such as India and China

Some of the key companies are MicroBiome Therapeutics, LLC; Seres Therapeutics; ENTEROME Bioscience; MaaT Pharma; Rebiotix, Inc.; Ritter Pharmaceuticals; Second Genome, Inc.; and OpenBiome

High investment on research and development of new drugs and investigation of available drugs for more untapped applications are the main strategies undertaken by the key players

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2016

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on